Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.
about
The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic ReviewWhen to start aripiprazole therapy in patients with bipolar maniaPostmortem femoral blood reference concentrations of aripiprazole, chlorprothixene, and quetiapineAripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.Classics in Chemical Neuroscience: Aripiprazole.Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.Aripiprazole: pharmacology, efficacy, safety and tolerability.Clinical pharmacology of atypical antipsychotics: an update.The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.Aripiprazole: the evidence of its therapeutic impact in schizophreniaRadix Bupleuri ameliorates depression by increasing nerve growth factor and brain-derived neurotrophic factor.Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.Effects of dopamine D2/D3 receptor ligands on food-cocaine choice in socially housed male cynomolgus monkeys.Prolactin serum concentrations during aripiprazole treatment in youth.Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study.Pharmacokinetics and metabolism update for some recent antipsychotics.Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients.Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment.Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.Aripiprazole: a review of its use in the management of schizophrenia in adults.Toxicological assessment of drugs that affect the endocrine system in puberty-related disorders.Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17.Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder.Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole.Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders.Aripiprazole, a Drug that Displays Partial Agonism and Functional Selectivity.Twice-weekly aripiprazole for treating children and adolescents with tic disorder, a randomized controlled clinical trial.Delusional parasitosis of face in a factory workerImpact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial.Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control.Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans.Adsorptive stripping voltammetric methods for determination of aripiprazole.Treatment in risperidone-induced amenorrhoea.The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.
P2860
Q26748677-03F24527-F25F-422E-9578-3D814325F4E4Q27014860-C151E8E5-A55E-4C64-A6A8-BE5312F8BC5EQ28250242-79A05A2B-98A7-4F5C-A3AA-B1FFC4D3A452Q33614458-EF821A46-ECC9-4F42-9C7C-BB1526B16296Q33866125-9E333475-9C2D-4F56-962A-061D9B2BBAB5Q34011162-A6401CE2-B6FF-4D16-9D61-89760CFD3ACCQ34558285-DF8F1181-C168-42CD-AAEC-5D991E6868C3Q35728228-5F7F2A35-5CCD-4905-9C4A-DF4F83650DC4Q35731977-36DC2CCF-8AF3-4F2E-837F-B2A86E59003FQ35876413-18ABF0B2-071E-4F03-8AB9-CDA65A8E9DCAQ35959514-38198D07-3B18-45A7-B969-ADB558CDE678Q36237653-07CF127B-2E9B-478B-9012-8628FD192FABQ36573210-B6274277-1822-426B-860F-9A9B64E45B6CQ36853126-2B1A3E58-291D-4649-A12B-899FE8DF7CC0Q37175786-1CD2E607-AB86-4110-A5C8-075F7C4AB62AQ37638755-C9EEF624-CFAD-49F0-97BC-C2E01E0D4C4DQ37663584-0642B7F8-7DFC-49F3-9059-2C0E8BD6E363Q37863118-96A1BB6F-4E7B-4B98-9EC1-6CB472A9B39BQ37866291-C575BAEF-3F21-4C4E-B02D-CF4FFE60B3D3Q37947687-FC99E6AA-8AF2-4599-A66A-118E940B945CQ37970762-C6D57A78-2D5E-423B-BF6E-6B24870DCE4CQ37980517-5D6C24B2-8027-454A-BA7A-FF2378EF9DCCQ38116106-CE997F21-8495-4E16-B6AD-73E8AFBD8161Q38122151-B39CD4B9-E991-4C1C-B7C0-014DE46C35E0Q38176566-FFBDCB5B-6DE0-4C8B-A31D-4C780031EF25Q38810111-006976B3-E490-4615-B7F2-EBEF747711C7Q38889269-43CF5FE9-4D81-4D46-B9C7-F114A2D42358Q39244947-97E37DDD-3EA7-48FB-8405-A041FA852A1FQ40972215-AA99BE9B-6E2C-4532-AC13-CDC1250FB7C1Q41773177-82BECCEA-3536-47FB-BA46-E211E89F071EQ42229238-FFE2CAFF-80FC-4A46-BE7F-1030F740A4E6Q42599261-E7F09729-E5FD-47D2-8D48-E3480EB2B57FQ45377706-71D62F59-6481-445F-8B17-28AD0963CC60Q46298093-ECEB03D1-5CEE-4986-BE3F-30E599937D44Q47843882-0499A6C6-2BF0-4672-ABE3-B29A96FA11B6Q47895142-957C941A-BF34-4FD5-9D80-2216B51F7F43Q48318789-9FCA7CFE-12D2-43CF-B811-544A51926BB8Q49472268-B0C39279-8AFD-4652-A141-D17F5B28D52DQ51934394-71E34D8E-12D2-463A-8C5D-78FA03D3DC69Q53118030-1BD8102B-343A-42B9-88DA-D1A02333AF2B
P2860
Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@ast
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@en
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@nl
type
label
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@ast
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@en
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@nl
prefLabel
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@ast
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@en
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics, tolerability ...... in normal healthy volunteers.
@en
P2093
Daniel E Salazar
Steven L Bramer
Suresh Mallikaarjun
P2860
P304
P356
10.1177/0091270003261901
P577
2004-02-01T00:00:00Z